APPLICATION PORTFOLIO COMPOSITION AND GENERIC MEDICINE REGISTRATION OUTPUTS ACROSS REGULATORY AUTHORITIES IN EMERGING PHARMACEUTICAL MARKETS

This analysis examines whether application portfolio patterns correspond to generic medicine registration output, addressing the interpretation of administrative counts in international regulatory benchmarking. Published administrative records provide 20 complete annual observations across six East African regulatory jurisdictions between 2020 and 2023. Descriptive distributions, authority comparisons and exploratory sample restrictions distinguish incoming applications from completed approvals. Rwanda accounts for 88.20 percent of recorded new active substance applications, whereas mainland Tanzania and Uganda contribute 70.62 percent of generic approvals. Generic application receipts and approvals move together in some periods but diverge in others, while applications for medicines prequalified by the World Health Organization show no consistent correspondence with generic output. Among four continuously observed jurisdictions, generic receipts increased by 13.39 percent between the endpoints while approvals decreased by 75.76 percent. Excluding one disputed observation changes pooled magnitudes without removing this descriptive distinction. The findings refine a capacity constrained processing perspective by separating incoming demand from completed decisions. International benchmarking should preserve these distinctions and use linked application histories before interpreting annual volumes as regulatory efficiency.